Interactions between malaria parasites and the host immune system.

Malaria remains one of the greatest impediments to development in many tropical regions of the world. Understanding host immune responses to malaria parasites is crucial for the effective design and implementation of new vaccines and drugs. Recent research has seen the identification of the first pattern recognition receptor (TLR9) on dendritic cells for a defined product of malaria infection (hemozoin). In addition, progress has been made in understanding the role of dendritic cell subsets in malaria, and how they promote specific components of the host immune response. Potentially important advances in vaccine design have also been made by inserting a Plasmodium sporozoite epitope into the yellow fever vaccine 17D, as well as using a whole, live-attenuated sporozoite vaccine.

[1]  W. Weidanz,et al.  Antibody-independent immunity to reinfection malaria in B-cell-deficient mice , 1983, Infection and immunity.

[2]  C. Rice,et al.  Yellow fever 17D as a vaccine vector for microbial CTL epitopes , 2005, The Journal of experimental medicine.

[3]  Thomas A. Smith,et al.  A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.

[4]  Ana Rodriguez,et al.  Malaria Blood Stage Suppression of Liver Stage Immunity by Dendritic Cells , 2003, The Journal of experimental medicine.

[5]  M. Molyneux,et al.  Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection , 2004, The Lancet.

[6]  Dragana Jankovic,et al.  Vaccination with Novel Immunostimulatory Adjuvants against Blood-Stage Malaria in Mice , 2003, Infection and Immunity.

[7]  J. Langhorne,et al.  Direct activation of dendritic cells by the malaria parasite, Plasmodium chabaudi chabaudi , 2001, European journal of immunology.

[8]  W. Ballou,et al.  Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys. , 2004, The American journal of tropical medicine and hygiene.

[9]  J. Burns,et al.  Immunity to blood-stage murine malarial parasites is MHC class II dependent. , 2003, Immunology letters.

[10]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[11]  C. Miyaji,et al.  Expansion of unconventional T cells with natural killer markers in malaria patients. , 2003, Parasitology international.

[12]  Stuart M. Brown,et al.  Infectivity-associated Changes in the Transcriptional Repertoire of the Malaria Parasite Sporozoite Stage* , 2002, The Journal of Biological Chemistry.

[13]  D. Webster,et al.  Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans , 2003, Nature Medicine.

[14]  C. Coban,et al.  Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin , 2005, The Journal of experimental medicine.

[15]  J. Burns,et al.  CD28 Costimulation Is Required for the Expression of T-Cell-Dependent Cell-Mediated Immunity against Blood-Stage Plasmodium chabaudi Malaria Parasites , 2004, Infection and Immunity.

[16]  E. Riley,et al.  Innate Immune Response to Malaria: Rapid Induction of IFN-γ from Human NK Cells by Live Plasmodium falciparum-Infected Erythrocytes1 , 2002, The Journal of Immunology.

[17]  H. Okada,et al.  Escape of malaria parasites from host immunity requires CD4+CD25+ regulatory T cells , 2004, Nature Medicine.

[18]  K. Bojang,et al.  Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. , 2003, The Journal of infectious diseases.

[19]  Danny W. Wilson,et al.  Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum , 2002, The Lancet.

[20]  R. Elias,et al.  Role of CD28 in Polyclonal and Specific T and B Cell Responses Required for Protection against Blood Stage Malaria1 , 2005, The Journal of Immunology.

[21]  Wenjiang J. Fu,et al.  Differentiating the pathologies of cerebral malaria by postmortem parasite counts , 2004, Nature Medicine.

[22]  S. Kappe,et al.  Genetically modified Plasmodium parasites as a protective experimental malaria vaccine , 2005, Nature.

[23]  R. Snow,et al.  Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk? , 2004, The American journal of tropical medicine and hygiene.

[24]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[25]  D. Seilhean,et al.  Perforin-Dependent Brain-Infiltrating Cytotoxic CD8+ T Lymphocytes Mediate Experimental Cerebral Malaria Pathogenesis 1 , 2003, The Journal of Immunology.

[26]  M. Good,et al.  Heterologous Immunity in the Absence of Variant-Specific Antibodies after Exposure to Subpatent Infection with Blood-Stage Malaria , 2005, Infection and Immunity.

[27]  M. Olivier,et al.  Hemozoin Induces Macrophage Chemokine Expression through Oxidative Stress-Dependent and -Independent Mechanisms1 , 2005, The Journal of Immunology.

[28]  M. Gatton,et al.  Inhibition of 19-kDa C-Terminal Region of Merozoite Surface Protein-1-Specific Antibody Responses in Neonatal Pups by Maternally Derived 19-kDa C-Terminal Region of Merozoite Surface Protein-1-Specific Antibodies but Not Whole Parasite-Specific Antibodies1 , 2004, The Journal of Immunology.

[29]  R. Good,et al.  Transcriptional profiling reveals suppressed erythropoiesis, up-regulated glycolysis, and interferon-associated responses in murine malaria. , 2004, The Journal of infectious diseases.

[30]  P. Smooker,et al.  Induction of Specific T-Cell Responses, Opsonizing Antibodies, and Protection against Plasmodium chabaudi adami Infection in Mice Vaccinated with Genomic Expression Libraries Expressed in Targeted and Secretory DNA Vectors , 2003, Infection and Immunity.

[31]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[32]  M. Mota,et al.  Malaria Vaccines: Back to the Future? , 2005, Science.

[33]  D. Kwiatkowski,et al.  Response of the Splenic Dendritic Cell Population to Malaria Infection , 2004, Infection and Immunity.

[34]  Laurent Kiger,et al.  Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells , 2005, Nature Biotechnology.

[35]  A. Avery,et al.  Dendritic Cells from Malaria-Infected Mice Are Fully Functional APC 1 , 2004, The Journal of Immunology.

[36]  R. Snow,et al.  The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa. , 2004, The American journal of tropical medicine and hygiene.

[37]  A. Pain,et al.  Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells , 1999, Nature.

[38]  P. Kremsner,et al.  IFN-γ and IL-10 Mediate Parasite-Specific Immune Responses of Cord Blood Cells Induced by Pregnancy-Associated Plasmodium falciparum Malaria1 , 2005, The Journal of Immunology.

[39]  E. Riley,et al.  Differential Induction of TGF-β Regulates Proinflammatory Cytokine Production and Determines the Outcome of Lethal and Nonlethal Plasmodium yoelii Infections 1 , 2003, The Journal of Immunology.

[40]  V. A. Stewart,et al.  Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway1 , 2004, The Journal of Immunology.

[41]  L. Rénia,et al.  On the Pathogenic Role of Brain-Sequestered αβ CD8+ T Cells in Experimental Cerebral Malaria1 , 2002, The Journal of Immunology.

[42]  M. Siomos,et al.  Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. , 2003, Immunity.